Professor Steve Nicholls is the inaugural Director of the Victorian Heart Institute and a Professor of Cardiology at Monash University. He is the Director at MonashHeart and is also the inaugural Director of the Victorian Heart Hospital which opened in February 2023. Professor Nicholls is a preventive cardiologist. His clinical interest is focused on identifying those at risk of heart disease earlier, and more effectively, and preventing catastrophic cardiovascular events from occurring. He is committed to solutions which improve equity across risk and management, focusing on women’s heart health and other under-served populations. His work spans the translational spectrum from the lab bench to the bedside, with a focus on understanding the factors that promote plaque formation, novel vascular imaging and leadership of large-scale clinical trials of new therapies designed to reduce the risk of heart disease. He is Chair of the Australian Atherosclerosis Society Clinical Council, Australia and New Zealand Alliance for Cardiovascular Trials, Asia Pacific Cardiometabolic Consortium, President of the Cardiac Society of Australia and New Zealand and a Fellow of the Australian Academy of Health and Medical Sciences.

Presenter of 6 Presentations

Recent therapeutic options for LDL-C management (ID 1636)

Session Type
Industry Session
Date
Sun, 21.05.2023
Session Time
14:00 - 15:15
Room
Hall: Heinrich Otto Wieland
Lecture Time
14:15 - 14:35

Moderator Led Q&A (ID 1648)

Session Type
Industry Session
Date
Mon, 22.05.2023
Session Time
14:45 - 15:30
Room
Hall: Rudolf Schönheimer
Lecture Time
15:15 - 15:30

Anitschkow Lecture: Personalised Prevention of Atherosclerotic Cardiovascular Disease (ID 1417)

Session Type
Plenary
Date
Sun, 21.05.2023
Session Time
18:30 - 20:02
Room
Hall: Anitschkow
Lecture Time
19:22 - 20:02

Panel discussion and Q&A (ID 1639)

Session Type
Industry Session
Date
Sun, 21.05.2023
Session Time
14:00 - 15:15
Room
Hall: Heinrich Otto Wieland
Lecture Time
15:00 - 15:10

Cholesterol Roundtable case study (ID 1420)

Session Type
Parallel Session
Date
Mon, 22.05.2023
Session Time
13:30 - 14:30
Room
Hall: Rudolf Schönheimer
Lecture Time
13:50 - 14:00

O065 - IMPACT OF BEMPEDOIC ACID ON CARDIOVASCULAR EVENTS IN HIGH RISK PATIENTS WITH STATIN INTOLERANCE: THE CLEAR OUTCOMES STUDY (ID 1533)

Session Type
Late Breaker
Date
Tue, 23.05.2023
Session Time
15:45 - 17:15
Room
Hall: Rudolf Schönheimer
Lecture Time
16:55 - 17:05

Abstract

Background and Aims

Aim: The ATP citrate lyase inhibitor, bempedoic acid, has been demonstrated to reduce low-density lipoprotein (LDL) cholesterol, but is effect on cardiovascular outcomes has not been previously studied.

Methods

Methods: 13,970 patients at high cardiovascular risk, LDL-C >100 mg/dL and documented statin intolerance were treated with bempedoic acid 180 mg or matching placebo daily for at least 24 months. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization.

Results

Results: Bempedoic acid produced greater lowering of LDL-cholesterol (21.1 vs 0.6) from a baseline of 139 mg/dL. Less primary endpoint events were observed in the bempedoic acid group (11.7 vs 13.3%, hazard ratio (HR) 0.87, 95% CI 0.79 to 0.96, P=0.004). Bempedoic acid treated patients also demonstrated a lower rate of (1) the composite of cardiovascular death, myocardial infarction or stroke (8.2 vs 9.5%, HR 0.85, 95% CI 0.76 to 0.96, P=0.006), (2) myocardial infarction (3.7 vs 4.8%, HR 0.77, 95%, CI 0.66 to 0.91, P=0.002) and (3) coronary revascularization (6.2 vs 7.6%, HR 0.81, 95% CI 0.72 to 0.92, P=0.001). No difference was observed between groups with regard to myalgia (5.6 vs 6.8%), while bempdoic acid treated patients were more likely to experience gout (3.1% vs. 2.1%), cholelithiasis (2.2% vs 1.2%), and small increases in serum creatinine, uric acid and hepatic enzymes.

Conclusions

Conclusions: Lowering levels of LDL-cholesterol with bempedoic acid associated with reductions in the rate of cardiovascular events in patients with statin intolerance.

Hide